ClearPoint Neuro, Inc.

Equities

CLPT

US18507C1036

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.8 USD +1.19% Intraday chart for ClearPoint Neuro, Inc. -0.29% +0.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stifel Adjusts Price Target on ClearPoint Neuro to $9 From $8, Maintains Buy Rating MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : ClearPoint Neuro, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M MT
ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024 CI
ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery CI
ClearPoint Neuro to Seek Acquisitions CI
ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model CI
ClearPoint Neuro, Inc. Announces Installation and First Procedure Using the Clearpoint Prism® Neuro Laser Therapy System and Navigation System At Kaleida Health in Buffalo CI
Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System CI
ClearPoint Neuro Shares Up 16% After Prelim. 4Q Revenue Beats Estimates DJ
Clinical Laserthermia Systems Gets SEK8 Million Order from ClearPoint Neuro; Stocks Rise MT
ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Lake Street Cuts ClearPoint Neuro Price Target to $11 From $15, Maintains Buy Rating MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : ClearPoint Neuro, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q3 Revenue $5.8M, vs. Street Est of $6.73M MT
ClearPoint Neuro, Inc. Provides Earnings Guidance for the Year 2023 CI
Stifel Initiates ClearPoint Neuro With Buy Rating, Price Target is $8 MT
Lake Street Adjusts Price Target on ClearPoint Neuro to $15 From $22, Maintains Buy Rating MT
ClearPoint Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q2 Revenue $6M, vs. Street Est of $5.9M MT
Transcript : ClearPoint Neuro, Inc., Q2 2023 Earnings Call, Aug 08, 2023
ClearPoint Neuro, Inc. Reaffirms Its Revenue Guidance for Full Year 2023 CI
ClearPoint Neuro, Inc.(NasdaqCM:CLPT) added to Russell Small Cap Comp Value Index CI
Chart ClearPoint Neuro, Inc.
More charts
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.72 USD
Average target price
10 USD
Spread / Average Target
+48.81%
Consensus
  1. Stock
  2. Equities
  3. Stock ClearPoint Neuro, Inc. - Nasdaq
  4. News ClearPoint Neuro, Inc.
  5. ClearPoint Neuro Appoints Mazin Sabra Chief Operating Officer